Vaccines
Moderna CEO Reflects on 2024 Challenges and Advances in Shareholder Letter
Moderna, shareholder letter, 2024 review, RSV vaccine, COVID-19 vaccine, mRNA medicines, Stéphane Bancel
Merck Acquires WuXi Biologics’ Irish Vaccine Facility in $500M Deal
Merck, WuXi Biologics, vaccine facility, Ireland, $500M deal, pharmaceutical manufacturing
BioNTech Resolves COVID-19 Vaccine Royalty Disputes with NIH and UPenn
BioNTech, COVID-19 vaccine, royalty disputes, NIH, UPenn, Pfizer, settlement agreements
Sanofi and SK Bioscience Enhance Partnership for Next-Generation Pneumococcal Conjugate Vaccines
Sanofi, SK Bioscience, Pneumococcal Conjugate Vaccines (PCVs), Next-Generation Vaccines, Pediatric and Adult Populations, Phase III Testing, PCV21
FDA Halts Pediatric RSV Vaccine Trials Due to Safety Concerns
RSV vaccines, pediatric trials, safety concerns, FDA hold, VAERD risk
Moderna’s RSV Vaccines Face Safety Concerns Over Severe Infections in Infants
Moderna, RSV vaccines, safety concerns, severe infections, infants, mRNA vaccines, FDA, advisory committee
GSK Extends Shingrix Collaboration with Zhifei in China, Explores RSV Vaccine Partnership
GSK, Zhifei, Shingrix, RSV vaccine, Arexvy, China, vaccine collaboration
Trump’s Re-Election: A Mixed Bag for Biopharma with M&A Upsides and Vaccine Concerns
Trump Administration, Biopharma, Mergers and Acquisitions, Vaccine Policy, Robert F. Kennedy Jr., FDA Independence, Inflation Reduction Act
Novavax Sells Czech Manufacturing Facility to Novo Nordisk for $200 Million
Novavax, Novo Nordisk, Czech manufacturing facility, cost-cutting, vaccine pipeline development
GSK Terminates Development of HBV Therapeutic Vaccine Due to Efficacy Failure
GSK, HBV, therapeutic vaccine, efficacy failure, clinical trial termination